Table 1 Conventional and modified BRASIL enrichment results based on binding affinity to the breast cancer MDA-MB-231 cell line and a counter selection with the non-tumorigenic MCF-10-2A cell line with the 7-mer and 12-mer libraries

Conventional

3.1 (5/27)

PRLNTSP

6.2 (1/17)

TTFNSFGRVAIE

3.1 (6/27)

PTLDVAP

6.2 (2/17)

TTFCSFGRVRIE

3.1 (8/27)

PQLNVSP

6.2 (3/17)

TTFNSFGRVRIE

3.1 (9/27)

PGAQVSP

6.2 (4/17)

TTFNSFGRVHWE

3.1 (10/27)

PRTNVAP

6.2 (5/17)

TTFNSFGKVRIE

3.1 (11/27)

PRKTVSP

6.2 (7/17)

TTYNSFGRVRIE

3.1 (12/27)

PAMNVSP

6.2 (8/17)

TTEYSFGRTSTL

3.1 (13/27)

PQENASP

6.2 (9/17)

DTFNSFGRVRIE

3.1 (19/27)

PSLNVSP

6.2 (10/17)

TTFNSFGRVRIQ

3.1 (20/27)

ARLNVAP

6.2 (12/17)

TTFNSFGRVRIE

3.1 (21/27)

TMLMVRP

6.2 (13/17)

TNFNDFKRVRGE

3.1 (22/27)

ARLNTQP

6.2 (14/17)

TTFSSFGRVRIG

3.1 (23/27)

PMMAVAP

6.2 (15/17)

TTFNSNGRVWIE

3.1 (26/27)

PRLNVSP

6.2 (16/17)

TTFNSFGRVRGG

3.1 (27/27)

PRLNVSP

6.2 (17/17)

TTFNSFYRVRIE

Consensus (overall %)

PRLNVSP (70%)

Consensus (overall %)

TTFNSFGRVRIE (86%)

BRASIL

1.3 (2/52)

PRQNQSP

5.3 (1/45)

WWFNSFGRVRIE

1.3 (3/52)

QLKNVTP

5.3 (3/45)

WAFNSFGRVRIE

1.3 (5/52)

PRLNVAT

5.3 (5/45)

WWFNKFGKVRIE

1.3 (6/52)

PRLNVTT

5.3 (14/45)

WWFNSFGRVRIE

1.3 (7/52)

PRWAVSP

5.3 (16/45)

IWFNSFFRVRIE

1.3 (8/52)

PRLNHSP

5.3 (19/45)

WWFFSFGRVRIE

1.3 (10/52)

PQMTAMP

5.3 (20/45)

GWFNSFGRWSWL

1.3 (11/52)

MFLNGAP

5.3 (23/45)

WWFNSFGRVRIE

1.3 (15/52)

TRLQVSP

5.3 (43/45)

WWFFSFGRWSWL

1.3 (19/52)

WRMAHSP

5.3 (45/45)

WWFNSFGRVRIE

Consensus (overall %)

PRLNVSP (60%)

Consensus (overall %)

WWFNSFGRVRIE (87%)